Tech Company Financing Transactions

CatalYm Funding Round

On 11/22/2022, CatalYm secured $49 million in Series C funding from Brandon Capital Partners, Jeito Capital and Bayern Kapital.

Transaction Overview

Company Name
Announced On
11/22/2022
Transaction Type
Venture Equity
Amount
$49,000,000
Round
Series C
Proceeds Purpose
The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Am Klopferspitz 19 Martinsried
Planegg, Martinsri, 82152
DE
Email Address
Overview
Operator of a biopharmaceutical company intended to transform cancer patients' lives by engaging their own immune systems. The company's services engage in developing antibodies that transform the tumor micro-environment and substantially improve treatment options by making tumors accessible and susceptible again to the patient's own immune system, enabling cancer patients to improve their survival and quality of life.
Profile
CatalYm LinkedIn Company Profile
Social Media
CatalYm Company Twitter Account
Company News
CatalYm News
Facebook
CatalYm on Facebook
YouTube
CatalYm on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Phil L'Huillier
  Phil L'Huillier LinkedIn Profile  Phil L'Huillier Twitter Account  Phil L'Huillier News  Phil L'Huillier on Facebook
Chief Financial Officer
Anne Burger
  Anne Burger LinkedIn Profile  Anne Burger Twitter Account  Anne Burger News  Anne Burger on Facebook
Chief Medical Officer
Eugen Leo
  Eugen Leo LinkedIn Profile  Eugen Leo Twitter Account  Eugen Leo News  Eugen Leo on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/22/2022: care.ai venture capital transaction
Next: 11/22/2022: Rosotics venture capital transaction

 

Share this article

 


Where The Data Comes From

We document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary